DE602006008583D1 - Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung - Google Patents
Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendungInfo
- Publication number
- DE602006008583D1 DE602006008583D1 DE602006008583T DE602006008583T DE602006008583D1 DE 602006008583 D1 DE602006008583 D1 DE 602006008583D1 DE 602006008583 T DE602006008583 T DE 602006008583T DE 602006008583 T DE602006008583 T DE 602006008583T DE 602006008583 D1 DE602006008583 D1 DE 602006008583D1
- Authority
- DE
- Germany
- Prior art keywords
- dosage forms
- bifeprunoxmesylate
- crystalline form
- stable crystalline
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- ONWKHSGOYGLGPO-UHFFFAOYSA-N methanesulfonic acid;7-[4-[(3-phenylphenyl)methyl]piperazin-1-yl]-3h-1,3-benzoxazol-2-one Chemical compound CS(O)(=O)=O.C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 ONWKHSGOYGLGPO-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65414905P | 2005-02-18 | 2005-02-18 | |
PCT/EP2006/060055 WO2006087369A1 (en) | 2005-02-18 | 2006-02-17 | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using them |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006008583D1 true DE602006008583D1 (de) | 2009-10-01 |
Family
ID=36383746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006008583T Active DE602006008583D1 (de) | 2005-02-18 | 2006-02-17 | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung |
Country Status (12)
Country | Link |
---|---|
US (1) | US7423040B2 (de) |
EP (1) | EP1853232B1 (de) |
AT (1) | ATE439831T1 (de) |
CA (1) | CA2598407A1 (de) |
DE (1) | DE602006008583D1 (de) |
DK (1) | DK1853232T3 (de) |
ES (1) | ES2331487T3 (de) |
HR (1) | HRP20090569T1 (de) |
PL (1) | PL1853232T3 (de) |
PT (1) | PT1853232E (de) |
SI (1) | SI1853232T1 (de) |
WO (1) | WO2006087369A1 (de) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435738B2 (en) | 2003-08-18 | 2008-10-14 | Solvay Pharmaceuticals, Inc. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
US7405216B2 (en) | 2004-08-18 | 2008-07-29 | Solvay Pharmaceuticals, B.V. | Stable crystalline form of bifeprunox mesylate (7-[4-([1,1′-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3H)-benzoxazolone monomethanesulfonate) |
US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
US7964604B2 (en) * | 2005-02-18 | 2011-06-21 | Solvay Pharmaceuticals B.V. | Bifeprunox mesylate maintenance dose compositions and methods for using the same |
US7786126B2 (en) | 2006-06-16 | 2010-08-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising SLV308 and a dopamine agonist |
US8106056B2 (en) | 2006-06-16 | 2012-01-31 | Solvay Pharmaceuticals B.V. | Combination preparations comprising bifeprunox and a dopamine agonist |
EP2059244A1 (de) * | 2006-08-31 | 2009-05-20 | Solvay Pharmaceuticals B.V. | Titrationsplan für bifeprunox zur behandlung von schizophrenie und kits zur verwendung damit |
US20090068290A1 (en) * | 2006-08-31 | 2009-03-12 | Michel Bourin | Bifeprunox doses for treating schizophrenia |
US20080132520A1 (en) * | 2006-08-31 | 2008-06-05 | Winsemius Antje A | Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds |
US20100119622A1 (en) * | 2008-09-15 | 2010-05-13 | Auspex Pharmaceuticals, Inc. | 3h-benzooxazol-2-one modulators of d2 receptor and/or 5-ht1a receptor |
EP2377850A1 (de) | 2010-03-30 | 2011-10-19 | Pharmeste S.r.l. | TRPV1-Vanilloidrezeptorantagonisten mit einem bizyklischen Teil |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE81975T1 (de) | 1984-12-21 | 1992-11-15 | Duphar Int Res | Arzneimittel mit psychotroper wirkung. |
DE69736704T2 (de) | 1996-03-29 | 2007-09-13 | Duphar International Research B.V. | Piperazin- und piperidin- derivate |
TW530054B (en) | 1997-09-24 | 2003-05-01 | Duphar Int Res | New piperazine and piperidine compounds |
UA71590C2 (en) | 1998-11-13 | 2004-12-15 | Duphar Int Res | Piperazine and piperidine derivatives |
CA2310950C (en) | 2000-04-03 | 2005-11-08 | Janssen Pharmaceutica N.V. | An efficacious dosage regiment of galantamine that reduces side effects |
AR034206A1 (es) | 2001-02-16 | 2004-02-04 | Solvay Pharm Bv | Un procedimiento para la preparacion de mesilatos de derivados de piperazina y dichos mesilatos |
AR045362A1 (es) * | 2003-08-18 | 2005-10-26 | Solvay Pharm Bv | Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona |
US7596407B2 (en) | 2004-03-26 | 2009-09-29 | Solvay Pharmaceuticals, B.V. | Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
CA2581143C (en) | 2004-09-21 | 2015-03-31 | Shandong Luye Pharmaceutical Co., Ltd. | Long acting sustained-release formulation containing dopamine receptor agonist and the preparation method thereof |
US7423040B2 (en) | 2005-02-18 | 2008-09-09 | Irene Eijgendaal | Stable crystalline form of bifeprunox mesylate, dosage forms thereof and methods for using same |
RU2394821C2 (ru) | 2005-08-22 | 2010-07-20 | Солвей Фармасьютикал Б.В. | N-оксиды как пролекарства производных пиперазина и пиперидина |
-
2006
- 2006-02-16 US US11/354,652 patent/US7423040B2/en not_active Expired - Fee Related
- 2006-02-17 SI SI200630444T patent/SI1853232T1/sl unknown
- 2006-02-17 AT AT06708346T patent/ATE439831T1/de active
- 2006-02-17 DE DE602006008583T patent/DE602006008583D1/de active Active
- 2006-02-17 CA CA002598407A patent/CA2598407A1/en not_active Abandoned
- 2006-02-17 EP EP06708346A patent/EP1853232B1/de active Active
- 2006-02-17 WO PCT/EP2006/060055 patent/WO2006087369A1/en active Application Filing
- 2006-02-17 PL PL06708346T patent/PL1853232T3/pl unknown
- 2006-02-17 ES ES06708346T patent/ES2331487T3/es active Active
- 2006-02-17 PT PT06708346T patent/PT1853232E/pt unknown
- 2006-02-17 DK DK06708346T patent/DK1853232T3/da active
-
2009
- 2009-10-26 HR HR20090569T patent/HRP20090569T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
PL1853232T3 (pl) | 2010-01-29 |
US7423040B2 (en) | 2008-09-09 |
SI1853232T1 (sl) | 2010-01-29 |
ATE439831T1 (de) | 2009-09-15 |
EP1853232A1 (de) | 2007-11-14 |
DK1853232T3 (da) | 2009-12-14 |
HRP20090569T1 (hr) | 2009-11-30 |
EP1853232B1 (de) | 2009-08-19 |
PT1853232E (pt) | 2009-11-12 |
ES2331487T3 (es) | 2010-01-05 |
WO2006087369A1 (en) | 2006-08-24 |
CA2598407A1 (en) | 2006-08-24 |
US20060194812A1 (en) | 2006-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602006008583D1 (de) | Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung | |
DE602005005810D1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
ATE459621T1 (de) | Benzisoxazolpiperidinverbindungen und verfahren zu deren anwendung | |
DE602004022424D1 (de) | Proteasominhibitoren und verfahren zu deren anwendung | |
NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
DE602005023763D1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
EA200970113A1 (ru) | Бензофуро- и бензотиенопиримидиновые модуляторы гистаминового рецептора н | |
EA200700118A1 (ru) | Амидосоединения и их применение в качестве лекарственных средств | |
DE602006010243D1 (de) | 4-(Phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamid Derivate als MEK Inhibitoren zur Behandlung von hyperproliferativen Erkrankungen | |
DE602004032522D1 (de) | Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung | |
BRPI0513367A (pt) | arilidenos para o tratamento de doenças mediadas pelo receptor alfa relacionado a estrogênio | |
DE602005015862D1 (de) | Verwendung von k-252a und kinasehemmern zur vorbeugung und behandlung von hmgb1-assoziierten pathologien | |
DE602006010400D1 (de) | Olanzapin-analoga und verfahren zu ihrer verwendung | |
DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
ATE425961T1 (de) | Salze substituierter allophansaureester und deren verwendung in arzneimitteln | |
ATE435858T1 (de) | Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen | |
EA200901484A1 (ru) | СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR | |
ATE422201T1 (de) | 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen | |
ATE524463T1 (de) | 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung | |
EA200701813A1 (ru) | Новые амидозамещенные 6-фенилфенантридины | |
DE602007011756D1 (de) | Verwendung eines p38-kinasehemmers zur behandlung von psychiatrischen erkrankungen | |
CY1110156T1 (el) | Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης | |
ATE446757T1 (de) | 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen | |
ATE453628T1 (de) | Nucleosidderivate und deren therapeutische verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |